When Hillary Clinton’s transition team was announced last week, much of the coverage focused (appropriately) on the health care experience of one co-chair, Neera Tanden. But another co-chair, former Michigan Governor Jennifer Granholm, also has an interesting history with the largest US pharma company – and, indirectly, with a member of Donald Trump’s transition team.

The presidential campaign is about to begin in earnest, and for biopharma companies, the biggest question is what the outcome will mean for the pricing climate in the US. It isn’t an easy question to answer.

Draft includes only a selection of price control policies that have been offered by presumptive nominee Hillary Clinton and candidate Sen. Bernie Sanders on the campaign trail.